Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 180 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)

Lupus Erythematosus, Systemic, Lupus Nephritis Phase2 United States
Singapore

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Sickle Cell Disease Phase1, Phase2 United States

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis Phase4 Germany
United Kingdom
United States

First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers

Healthy Volunteers Phase1 United Kingdom

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)

Solid Tumor Phase1, Phase2 United States

Iptacopan in Patients With ANCA Associated Vasculitis

Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis Phase2 China

Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease Phase3 United States

Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation

Hidradenitis Suppurativa Russian Federation

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis Phase2 United States

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Metastatic Neuroendocrine Prostate Cancer Phase1 Spain
France